SAMH
PHAS

Shanda Asset Management Holdings’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Shanda Asset Management Holdings’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,500
Closed -$140K – 113
2020
Q2 		$140K Buy
+30,500
New +$135K 0.01% 92

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Shanda Asset Management Holdings's PHAS Position: Q3 2020 in Review

Shanda Asset Management Holdings sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2020, closing a stake of 30,500 shares — an estimated $140K sold.

Shanda Asset Management Holdings first reported a position in PHAS in Q2 2020 and held it in 1 quarter. The position peaked at $140K in Q2 2020. 50 funds tracked by Wall St. Rank hold PHAS as of Q3 2020.

  • Shanda Asset Management Holdings reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Shanda Asset Management Holdings sold 30,500 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $140K.
  • Shanda Asset Management Holdings first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Shanda Asset Management Holdings's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $140K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2020, filed 16 Nov 2020.